13 Results

People

  1. Abdel-Wahab
    Abdel-Wahab
  2. Devlin
    Devlin
  3. Dogan
    Dogan
  4. Grieve
    Grieve
  5. Mi
    Mi
  6. Owens
    Owens
  7. Seshan
    Seshan
  8. Tallman
    Tallman
  9. Zelenetz
    Zelenetz
  10. Batlevi
    Batlevi

Groups

  1. Biostatistics Service (13)
  2. Center for Hematologic Malignancies (13)
  3. Department of Medicine (13)
  4. Epidemiology and Biostatistics (13)
  5. Executive Committee, Center for Hematologic Malignancies (13)
  6. GSK Faculty (13)
  7. Hematologic Malignancies, Division of (13)
  8. Human Oncology and Pathogenesis Program (13)
  9. Survivorship Research (13)
  10. Tow Center for Developmental Oncology (TCDO) (13)
  1. "Omar Abdel-Wahab"
  2. "Survivorship Research"
  3. "Biostatistics Service"
Formats
  1. Journal Article (8)
  2. Meeting Abstract (5)
Groups
  1. Biostatistics Service (13)
  2. Center for Hematologic Malignancies (13)
  3. Department of Medicine (13)
  4. Epidemiology and Biostatistics (13)
  5. Executive Committee, Center for Hematologic Malignancies (13)
  6. GSK Faculty (13)

More Groups

People
  1. Omar Abdel-Wahab (13)
  2. Ahmet Dogan (5)
  3. Andrew Zelenetz (4)
  4. Clare Grieve (4)
  5. Colette Owens (4)
  6. Joanna Mi (4)

More People

Years
  1. 2023 (3)
  2. 2021 (3)
  3. 2020 (1)
  4. 2019 (2)
  5. 2015 (2)
  6. 2013 (1)

More Years

Publications
  1. Blood (3)
  2. British Journal of Haematology (2)
  3. American Journal of Hematology (1)
  4. BJU International (1)
  5. Blood Advances (1)
  6. European Urology (1)

More Publications

Publishers
  1. American Society of Hematology (4)
  2. Elsevier Science, Inc. (2)
  3. John Wiley & Sons (2)
  4. Wiley Blackwell (2)
  5. John Wiley & Sons, Inc. (1)
  6. Massachusetts Medical Society (1)

More Publishers

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
    Journal Article

    Stahl, M.; Derkach, A.; Farnoud, N.; Bewersdorf, J. P.; Robinson, T.; Famulare, C.; Cho, C.; Devlin, S.; Menghrajani, K.; Patel, M. A.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia
    Meeting Abstract

    Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease
    Journal Article

    Diamond, E. L.; Reiner, A. S.; Buthorn, J. J.; Shuk, E.; Applebaum, A. J.; Hyman, D. M.; Abdel-Wahab, O.; Rampal, R.; Janku, F.; Brewer, K.; more...
    Blood Advances (2019)

    Fulltext@MSK | Save
  • Efficacy of MEK inhibition in patients with histiocytic neoplasms
    Journal Article

    Diamond, E. L.; Durham, B. H.; Ulaner, G. A.; Drill, E.; Buthorn, J.; Ki, M.; Bitner, L.; Cho, H.; Young, R. J.; Francis, J. H.; more...
    Nature (2019)

    Fulltext@MSK | Save
  • Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia
    Journal Article

    Tiacci, E.; Park, J. H.; De Carolis, L.; Chung, S. S.; Broccoli, A.; Scott, S.; Zaja, F.; Devlin, S.; Pulsoni, A.; Chung, Y. R.; more...
    New England Journal of Medicine (2015)

    Fulltext@MSK | Save